Luisa Petrone
Overview
Explore the profile of Luisa Petrone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Capezzone M, Torregrossa L, Poma A, Cartocci A, Petrone L, Sparano C, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075565
Thyroid cancer (TC) is the most common endocrine malignancy, and its incidence continues to rise worldwide [...].
2.
Campi I, Censi S, Prodam F, Petrone L, Brigante G, Porcelli T, et al.
Eur J Endocrinol
. 2024 Sep;
191(4):407-415.
PMID: 39327977
Objective: Decreased survival and higher cardiovascular morbidity have been recently reported in a UK cohort of 61 RTHβ patients, but there is no evidence from other countries. Design: Retrospective cohort...
3.
Grani G, DElia S, Puxeddu E, Morelli S, Arvat E, Nervo A, et al.
J Clin Endocrinol Metab
. 2024 Aug;
PMID: 39150986
Context: The utility of thyroglobulin (Tg) in the follow-up of differentiated thyroid cancer (DTC) patients has been well-documented. Although third-generation immunoassays have improved accuracy, limitations persist (interfering anti-Tg antibodies and...
4.
Croce L, Teliti M, Chytiris S, Sparano C, Coperchini F, Villani L, et al.
Eur J Endocrinol
. 2024 Feb;
190(2):165-172.
PMID: 38298148
Objective: To compare the American Thyroid Association (ATA) risk staging of histologically proven papillary thyroid cancer (PTC) in patients who received a presurgery cytologic result of either indeterminate thyroid nodules...
5.
Zago E, Galluzzo A, Pradella S, Antonuzzo L, Maggi M, Petrone L, et al.
Endocrine
. 2023 Oct;
83(1):26-40.
PMID: 37851242
Purpose: Cabozantinib is an oral multi-tyrosine kinase inhibitor (TKI) that has been approved in Europe for advanced renal cell carcinoma, hepatocellular carcinoma, locally advanced and metastatic medullary thyroid carcinoma (MTC)...
6.
Giudici F, Fortuna L, Russo E, Badii B, Coratti F, Staderini F, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37174047
The sporadic parathyroid pathology of surgical interest is primarily limited to lesions that are the cause of hormonal hyperfunction (primary hyperparathyroidism). In recent years, parathyroid surgery has evolved significantly, and...
7.
Sparano C, Adornato V, Puccioni M, Zago E, Perigli G, Badii B, et al.
Front Oncol
. 2023 Mar;
13:1120799.
PMID: 36910603
Introduction: Calcitonin is the most specific marker for medullary thyroid carcinoma, thus, low detectable calcitonin values after surgery can conceal persistent disease. The present study aimed to explore the prognostic...
8.
Sparano C, Rotondi M, Verdiani V, Brunori P, Castiglione F, Bartoli C, et al.
J Endocr Soc
. 2022 Nov;
6(12):bvac157.
PMID: 36397778
Context: Despite the wide revision of current guidelines, the management of papillary thyroid microcarcinoma (mPTC) still has to be decided case by case. There is conflicting evidence about the role...
9.
Della Bella C, Antico A, Panozzo M, Capitani N, Petrone L, Benagiano M, et al.
Front Immunol
. 2022 Aug;
13:952674.
PMID: 35911678
Human gastric autoimmunity [autoimmune gastritis (AIG)] is characterized by inflammation of the gastric mucosa and parietal cell loss. The gastric parietal cell proton pump H/K-adenosine triphosphatase (H/K-ATPase) is the major...
10.
Della Bella C, Antico A, Panozzo M, Capitani N, Benagiano M, Petrone L, et al.
Front Immunol
. 2022 Apr;
13:887256.
PMID: 35479078
Pernicious anemia (PA) is a megaloblastic anemia consisting of hematological, gastric and immunological alterations. The immunopathogenesis of PA is sustained by both autoantibodies (e.g. intrinsic factor (IFA) antibodies and anti...